Zobrazeno 1 - 10
of 21
pro vyhledávání: '"MGMT-Unmethylated Glioblastoma"'
Autor:
Maasa Seaberg, Jann N. Sarkaria, Hok Seum Wan Chan Tseung, S. Keith Anderson, M. Zakhary, Yan Zhang, Debra H. Brinkmann, Elizabeth Yan, Brian Kabat, Michael W. Ruff, Bradley J. Kemp, Paul D. Brown, Joon H. Uhm, Diane Vogen, Val J. Lowe, Christopher H. Hunt, Timothy J. Kaufmann, Sani H. Kizilbash, Nadia N. Laack, Deanna H. Pafundi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 110:1383-1395
Purpose Our previous work demonstrated that 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) positron emission tomography (PET) is sensitive and specific for identifying regions of high density and biologically aggressive glioblastoma. The pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05d28ae3563b310a2620b68538619e30
https://doi.org/10.1016/j.ijrobp.2021.03.032
https://doi.org/10.1016/j.ijrobp.2021.03.032
Autor:
Clemens Seidel, Katharina Sahm, Thomas Zeyen, Sotirios Bisdas, Frank A. Giordano, Elena Sperk, Sied Kebir, Julian P Layer, Ulrich Herrlinger, Sonia Leonardelli, Martin Glas, Lea Friker, Torsten Pietsch, Christina Schaub, Peter Hambsch, Michael Hölzel
Publikováno v:
Neuro Oncol
BACKGROUND Preclinical studies showed that CXCL12-mediated influx of highly angiogenic monocytes/macrophages is a key driver of tumor re-vascularization and re-growth after radiotherapy (RT) of glioblastoma (GBM). We report findings from a phase I/II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e295cf828fb360634306c6dddeec1c
Autor:
Lorenzo Trippa, David Meredith, E. Antonio Chiocca, Mehdi Touat, Lakshmi Nayak, Mary Welch, David Schiff, Jack Geduldig, Omar Arnaout, Louis B. Nabors, Christine McCluskey, Rameen Beroukhim, Thomas Kaley, Mikael L. Rinne, Sandro Santagata, Howard Colman, Shyam K. Tanguturi, Manmeet Ahluwalia, Brian M. Alexander, Rifaquat Rahman, Daniel N. Cagney, Andrew B. Lassman, David A. Reardon, Patrick Y. Wen, Maria Lavallee, Geoffrey Fell, Ugonma Chukwueke, Heinrich Elinzano, Ayal A. Aizer, Keith L. Ligon, Jose Mcfaline-Figueroa, Fiona Watkinson, Isabel Arrillaga-Romany, Jaroslaw T. Hepel, Daphne A. Haas-Kogan, Lisa Doherty, Christine Lu-Emerson, Tracy T. Batchelor, Shanna Dowling, Wenya Linda Bi, Jennifer Brunno, Evanthia Galanis, Brittany Fisher-Longden, Jan Drappatz, Sarah C. Gaffey, Eudocia Q. Lee
Publikováno v:
Neuro Oncol
BACKGROUND CC-115 is an oral, CNS-penetrant, selective inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK). Both targets are important in glioblastoma; PI3K/Akt/mTOR signaling is hypera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1359aba25163584a46b0b39b1b4b697
https://europepmc.org/articles/PMC7650886/
https://europepmc.org/articles/PMC7650886/
Autor:
Yinsheng Chen, Chao Ke, Richard Schwartz, Zhongping Chen, Dennis M. Brown, Qunying Yang, Xiao-Jing Du, Zhenghe Chen, Sarath Kanekal, John Langlands, Jia-wei Li, Claire Kwan, Meiling Deng, Anne Steino, Ji Zhang, Jian Wang, Shao-xiong Wu, Fuhua Lin, Yonggao Mou, Jeffrey A. Bacha, Greg A. Johnson, Xiaobing Jiang, Ke Sai, Xue Ju, Xiangheng Zhang, Chengcheng Guo
Publikováno v:
Glioma, Vol 2, Iss 4, Pp 167-173 (2019)
Background and Aim: Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) gene, which confers a limited response to standard-of-care treatment with temozolomide (TMZ), resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0397a7cfb0051bed409bf042879e57f
http://www.jglioma.com/article.asp?issn=2589-6113
http://www.jglioma.com/article.asp?issn=2589-6113
Autor:
Marco G. Paggi, Andrea Pace, Veronica Villani, Giuseppe Lombardi, Caludia Abruzzese, Antonio Silvani, Giulia Cerretti, Marta Padovan, Dario Benincasa, Mario Caccese, Silvia Matteoni
Publikováno v:
Neuro Oncol
The poor prognosis of patients affected by glioblastoma (GBM) prompts the search for new and more effective therapies, particularly for GBMs with unmethylated MGMT. In this regard, drug repurposing, can represent a safe and inexpensive way to bring n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5c9cc1b14fad2ca916b4e6e2b3555b8
https://doi.org/10.1093/neuonc/noab196.237
https://doi.org/10.1093/neuonc/noab196.237
Autor:
Timothy Prior, MacLean Nasrallah, Stephen J Bagley, Eileen Maloney-Wilensky, Arati Desai, Zev A. Binder, Steven Brem, Wei-Ting Hwang, Donald M. O'Rourke
Publikováno v:
Neuro Oncol
BACKGROUND This study builds on the results of the University of Pennsylvania sponsored phase I study of a single peripheral infusion of chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor variant III (EGFRvIII) in recu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66980274cdcef6c33a030eedd8b024d
https://europepmc.org/articles/PMC6846993/
https://europepmc.org/articles/PMC6846993/
Autor:
Scott Lindhorst, William A. Vandergrift, Guilherme B. F. Porto, Sunil J. Patel, David Cachia, Mohammed Alshareef, Arabinda Das, Libby Kosnik Infinger, Abhay K. Varma
Publikováno v:
Journal of the Neurological Sciences. 418:117102
Temozolomide (TMZ) therapy is the standard of care for patients with glioblastoma (GBM). Clinical studies have shown that elevated levels of DNA repair protein O (6)-methylguanine-DNA methyltransferase (MGMT) or deficiency/defect of DNA mismatch repa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb2307b1abf0b7c4b445628457c57bca
https://doi.org/10.1016/j.jns.2020.117102
https://doi.org/10.1016/j.jns.2020.117102
Autor:
Claire Kwan, Richard Schwartz, Qunying Yang, Shao-xiong Wu, Sarath Kanekal, Gregory Johnson, Jia-Wei Lei, Anne Steino, Zhongping Chen, Dennis M. Brown, Chengcheng Guo, John Langlands, Jeffrey A. Bacha
Publikováno v:
Cancer Research. 80:CT273-CT273
Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care includes surgery followed by chemoirradiation and temozolomide (TMZ). An unmethylated promoter for O6-methylguanine DNA methyltransferase (MGMT) is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c2d142a30204d8efe6d55dc1a9c0d7f
https://doi.org/10.1158/1538-7445.am2020-ct273
https://doi.org/10.1158/1538-7445.am2020-ct273
Publikováno v:
Cancers 12:1099 (2020)
Cancers, Vol 12, Iss 1099, p 1099 (2020)
Cancers
Cancers, Vol 12, Iss 1099, p 1099 (2020)
Cancers
Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo- a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb6dd074a8105fcbcda0ba16ff5ae9d
https://doi.org/10.3390/cancers12051099
https://doi.org/10.3390/cancers12051099
Autor:
Lorena Lopez, Richard Schwartz, Zhongping Chen, Claire Kwan, Sarath Kanekal, Anne Steino, Jeffrey A. Bacha, John Langlands, Dennis Brown, Chengcheng Guo
Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care includes surgery followed by chemo-radiation and temozolomide. An unmethylated promoter for O6-methylguanine-DNA-methyltransferase (MGMT) is a validat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5587adfac21c02a1dc433d9135cd69d4
https://europepmc.org/articles/PMC6216509/
https://europepmc.org/articles/PMC6216509/